Petros Pharmaceuticals, Inc. Increase (Decrease) in Contract with Customer, Liability
Petros Pharmaceuticals, Inc. (PTPI) reported Increase (Decrease) in Contract with Customer, Liability of $1.30 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-15.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2023-11-15
- Petros Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-09-30 was $500.00K, a 81.48% decline year-over-year.
- Petros Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-06-30 was $400.00K, a 89.19% decline year-over-year.
- Petros Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-03-31 was $400.00K, a 42.86% decline year-over-year.
- Petros Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2022-09-30 was $2.70M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month |
|---|---|---|---|
| 2023-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-15 | $900.00K derived: sum of 2 quarters · filed 2023-11-15 | $1.30M 10-Q · filed 2023-11-15 |
| 2023-06-30 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $800.00K 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $400.00K 10-Q · filed 2023-05-15 | ||
| 2022-09-30 | $2.70M 10-Q/A · filed 2022-11-15 | $6.40M derived: sum of 2 quarters · filed 2023-08-14 | $7.60M 10-Q · filed 2023-11-15 |
| 2022-06-30 | $3.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $4.40M 10-Q · filed 2023-08-14 | |
| 2022-03-31 | $700.00K 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |